The Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labour and Welfare approved 4B5 (Table 1; global recommendation protocol) as a CDx for assessment of the indication for T-DXd in patients with unresectable or metastatic HER2-low breast cancer who have previously received chemotherapy for metastatic disease. This evidence concerns the gene ERBB2 and metastatic neoplasm.